Leap Therapeutics Inc (NASDAQ:LPTX)’s traded shares stood at 1.51 million during the last session, with the company’s beta value hitting 0.27. At the close of trading, the stock’s price was $3.60, to imply an increase of 9.42% or $0.31 in intraday trading. The LPTX share’s 52-week high remains $5.00, putting it -38.89% down since that peak but still an impressive 63.61% since price per share fell to its 52-week low of $1.31. The company has a valuation of $137.74M, with an average of 0.53 million shares in intraday trading volume over the past 10 days and average of 156.41K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Leap Therapeutics Inc (LPTX), translating to a mean rating of 1.40. Of 3 analyst(s) looking at the stock, 0 analyst(s) give LPTX a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.48.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
After registering a 9.42% upside in the last session, Leap Therapeutics Inc (LPTX) has traded red over the past five days. The 5-day price performance for the stock is 34.58%, and 36.88% over 30 days. With these gigs, the year-to-date price performance is -13.15%. Short interest in Leap Therapeutics Inc (NASDAQ:LPTX) saw shorts transact 0.9 million shares and set a 6.71 days time to cover.
The extremes give us $5.5 and $5.5 for target low and target high price respectively. As such, LPTX has been trading -52.78% off suggested target high and -52.78% from its likely low.
Leap Therapeutics Inc (LPTX) estimates and forecasts
Looking at statistics comparing Leap Therapeutics Inc share performance against respective industry, we note that the company has outperformed competitors. Leap Therapeutics Inc (LPTX) shares are 10.77% up over the last 6 months, with its year-to-date growth rate higher than industry average at 53.77% against 17.50%. Revenue is forecast to grow 5.90% this quarter before jumping 26.10% for the next one.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 28.36% for the past 5-year period. While 2024 is set for a 54.87% return in earnings, projections for the next 5 years are at -2.49% annually.
LPTX Dividends
Leap Therapeutics Inc has its next earnings report out on 2024-Nov-11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Leap Therapeutics Inc insiders hold 14.13% of total outstanding shares, with institutional holders owning 40.28% of the shares at 46.91% float percentage. In total, 40.28% institutions holds shares in the company.
We also have Vanguard Total Stock Market Index Fund and Simplify Exchange Traded Fds-Health Care ETF as the top two Mutual Funds with the largest holdings of the Leap Therapeutics Inc (LPTX) shares. Going by data provided on Jun 30, 2024 , Vanguard Total Stock Market Index Fund holds roughly 725.17 shares. This is just over 1.90% of the total shares, with a market valuation of $2.61 million. Data from the same date shows that the other fund manager holds a little less at 631.27, or 1.65% of the shares, all valued at about 2.27 million.
